10-Q Filing

TANKE BIOSCIENCES CORP CIK: 1452011 Q2 2013

Filing Information

Form Type	10-Q
Accession Number	`0001213900-13-004390`
Period End Date	20130630
Filing Date	20130815
Fiscal Year	2013
Fiscal Period	Q2
XBRL Instance	tnbi-20130630.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 80 Income Statement 92 Cash Flow Statement 74

Balance Sheet 80 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$4.72M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	13.32M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$10.03M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.17M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.70M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	13.32M	shares	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$231.84K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	13.32M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	13.32M	shares	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	-	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$1.99M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$2.38M	USD	Point-in-time
Inventories, net	`InventoryNet`	$1.41M	USD	Point-in-time
Inventories, net	`InventoryNet`	$2.08M	USD	Point-in-time
Loans to customer and supplier	`AccountsAndOtherReceivablesNetCurrent`	$2.95M	USD	Point-in-time
Loans to customer and supplier	`AccountsAndOtherReceivablesNetCurrent`	$2.89M	USD	Point-in-time
Other receivables	`OtherReceivables`	$901.48K	USD	Point-in-time
Other receivables	`OtherReceivables`	$483.88K	USD	Point-in-time
Prepayments	`AdvancesToSuppliers`	$9.03M	USD	Point-in-time
Prepayments	`AdvancesToSuppliers`	$8.84M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$8.17K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$132.75K	USD	Point-in-time
Deferred tax assets	`DeferredTaxAssetsNetCurrent`	$27.60K	USD	Point-in-time
Deferred tax assets	`DeferredTaxAssetsNetCurrent`	$27.04K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$21.92M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$22.37M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$4.81M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$5.26M	USD	Point-in-time
Construction in progress	`ConstructionInProgressGross`	$295.25K	USD	Point-in-time
Construction in progress	`ConstructionInProgressGross`	$1.10M	USD	Point-in-time
Intangible asset, net	`FiniteLivedIntangibleAssetsNet`	$1.24M	USD	Point-in-time
Intangible asset, net	`FiniteLivedIntangibleAssetsNet`	$1.19M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	-	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$134.74K	USD	Point-in-time
Total assets	`Assets`	$29.47M	USD	Point-in-time
Total assets	`Assets`	$28.85M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$843.16K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$646.65K	USD	Point-in-time
Advance from customers	`AdvancesFromCustomers`	$128.32K	USD	Point-in-time
Advance from customers	`AdvancesFromCustomers`	$292.73K	USD	Point-in-time
Other payables and accrued liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$844.37K	USD	Point-in-time
Other payables and accrued liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$942.79K	USD	Point-in-time
Income tax payable	`AccruedIncomeTaxesCurrent`	$1.92M	USD	Point-in-time
Income tax payable	`AccruedIncomeTaxesCurrent`	$1.84M	USD	Point-in-time
Convertible notes, net	`ConvertibleDebtCurrent`	$7.27M	USD	Point-in-time
Convertible notes, net	`ConvertibleDebtCurrent`	$7.51M	USD	Point-in-time
Current portion of long-term borrowings	`LongTermDebtCurrent`	$1.29M	USD	Point-in-time
Current portion of long-term borrowings	`LongTermDebtCurrent`	$1.27M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$12.70M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$12.10M	USD	Point-in-time
Advance from government grant	`GovernmentGrantsForResearchAndDevelopmentProjectsOutstanding`	$82.09K	USD	Point-in-time
Advance from government grant	`GovernmentGrantsForResearchAndDevelopmentProjectsOutstanding`	$37.95K	USD	Point-in-time
Long-term borrowings	`LongTermDebtNoncurrent`	$808.85K	USD	Point-in-time
Long-term borrowings	`LongTermDebtNoncurrent`	$792.57K	USD	Point-in-time
Total liabilities	`Liabilities`	$12.93M	USD	Point-in-time
Total liabilities	`Liabilities`	$13.59M	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 par value, 50,000,000 shares authorized, 13,324,083 issued and outstanding as of June 30, 2013 and December 31, 2012	`CommonStockValue`	$13.32K	USD	Point-in-time
Common stock, $0.001 par value, 50,000,000 shares authorized, 13,324,083 issued and outstanding as of June 30, 2013 and December 31, 2012	`CommonStockValue`	$13.32K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$12.22M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$12.22M	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$1.93M	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$2.49M	USD	Point-in-time
Statutory reserve	`StatutoryAccountingPracticesRetainedEarningsNotAvailableForDividends`	$373.41K	USD	Point-in-time
Statutory reserve	`StatutoryAccountingPracticesRetainedEarningsNotAvailableForDividends`	$373.41K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$658.87K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$1.17M	USD	Point-in-time
Total Tanke Biosciences Corporation stockholders' equity	`StockholdersEquity`	$15.75M	USD	Point-in-time
Total Tanke Biosciences Corporation stockholders' equity	`StockholdersEquity`	$15.71M	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$171.44K	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$169.92K	USD	Point-in-time
Total Equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.88M	USD	Point-in-time
Total Equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.92M	USD	Point-in-time
Total Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$28.85M	USD	Point-in-time
Total Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$29.47M	USD	Point-in-time

Income Statement 92 line items

Line Item	Tag	Value	Unit	Period
Net sales	`SalesRevenueNet`	$11.97M	USD	2 Qtrs
Net sales	`SalesRevenueNet`	$7.43M	USD	1 Quarter
Net sales	`SalesRevenueNet`	$10.24M	USD	2 Qtrs
Net sales	`SalesRevenueNet`	$5.58M	USD	1 Quarter
Costs of sales	`CostOfGoodsSold`	$4.69M	USD	1 Quarter
Costs of sales	`CostOfGoodsSold`	$6.75M	USD	2 Qtrs
Costs of sales	`CostOfGoodsSold`	$3.75M	USD	1 Quarter
Costs of sales	`CostOfGoodsSold`	$7.64M	USD	2 Qtrs
Gross profit	`GrossProfit`	$1.82M	USD	1 Quarter
Gross profit	`GrossProfit`	$4.33M	USD	2 Qtrs
Gross profit	`GrossProfit`	$3.49M	USD	2 Qtrs
Gross profit	`GrossProfit`	$2.74M	USD	1 Quarter
Selling expenses	`SellingExpense`	$1.09M	USD	2 Qtrs
Selling expenses	`SellingExpense`	$1.28M	USD	2 Qtrs
Selling expenses	`SellingExpense`	$622.86K	USD	1 Quarter
Selling expenses	`SellingExpense`	$548.18K	USD	1 Quarter
Administrative expenses	`GeneralAndAdministrativeExpense`	$1.98M	USD	2 Qtrs
Administrative expenses	`GeneralAndAdministrativeExpense`	$997.47K	USD	1 Quarter
Administrative expenses	`GeneralAndAdministrativeExpense`	$1.22M	USD	2 Qtrs
Administrative expenses	`GeneralAndAdministrativeExpense`	$680.23K	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$116.55K	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$14.76K	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$52.24K	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$26.43K	USD	2 Qtrs
Income from operations	`OperatingIncomeLoss`	$109.80K	USD	2 Qtrs
Income from operations	`OperatingIncomeLoss`	$1.50M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$149.69K	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$1.99M	USD	2 Qtrs
Other income	`OtherNonoperatingIncomeExpense`	$40.07K	USD	1 Quarter
Other income	`OtherNonoperatingIncomeExpense`	-	USD	2 Qtrs
Other income	`OtherNonoperatingIncomeExpense`	$43.34K	USD	2 Qtrs
Other income	`OtherNonoperatingIncomeExpense`	-	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$26.15K	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$169.45K	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$18.81K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$148.25K	USD	1 Quarter
Interest expense	`InterestExpense`	$254.44K	USD	2 Qtrs
Interest expense	`InterestExpense`	$368.78K	USD	1 Quarter
Interest expense	`InterestExpense`	$39.38K	USD	1 Quarter
Interest expense	`InterestExpense`	$741.87K	USD	2 Qtrs
Amortization of discount on notes	`AmortizationOfFinancingCosts`	$1.38M	USD	2 Qtrs
Amortization of discount on notes	`AmortizationOfFinancingCosts`	-	USD	1 Quarter
Amortization of discount on notes	`AmortizationOfFinancingCosts`	$690.90K	USD	1 Quarter
Amortization of discount on notes	`AmortizationOfFinancingCosts`	$402.39K	USD	2 Qtrs
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$585.92K	USD	1 Quarter
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$31.64K	USD	2 Qtrs
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$169.19K	USD	1 Quarter
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-477.55K	USD	2 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$430.20K	USD	2 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$53.51K	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$313.50K	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$85.61K	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$-563.16K	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$115.68K	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$272.41K	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-398.56K	USD	2 Qtrs
Net loss attributable to non-controlling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-5.00K	USD	2 Qtrs
Net loss attributable to non-controlling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	-	USD	2 Qtrs
Net loss attributable to non-controlling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-2.48K	USD	1 Quarter
Net loss attributable to non-controlling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	-	USD	1 Quarter
Net income (loss) attributable to Tanke Biosciences Corporation	`NetIncomeLoss`	$-398.56K	USD	2 Qtrs
Net income (loss) attributable to Tanke Biosciences Corporation	`NetIncomeLoss`	$272.41K	USD	1 Quarter
Net income (loss) attributable to Tanke Biosciences Corporation	`NetIncomeLoss`	$118.16K	USD	1 Quarter
Net income (loss) attributable to Tanke Biosciences Corporation	`NetIncomeLoss`	$-558.16K	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$-563.16K	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$115.68K	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$272.41K	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-398.56K	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$98.47K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$512.54K	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$380.57K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$210.96K	USD	2 Qtrs
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$496.25K	USD	1 Quarter
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$370.88K	USD	1 Quarter
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-187.61K	USD	2 Qtrs
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-50.62K	USD	2 Qtrs
Comprehensive income (loss) attributable to non-controlling interest	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	-	USD	2 Qtrs
Comprehensive income (loss) attributable to non-controlling interest	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	-	USD	1 Quarter
Comprehensive income (loss) attributable to non-controlling interest	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-1.52K	USD	2 Qtrs
Comprehensive income (loss) attributable to non-controlling interest	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$15.00	USD	1 Quarter
Comprehensive income (loss) attributable to Tanke Biosciences Corporation	`ComprehensiveIncomeNetOfTax`	$-49.10K	USD	2 Qtrs
Comprehensive income (loss) attributable to Tanke Biosciences Corporation	`ComprehensiveIncomeNetOfTax`	$-187.61K	USD	2 Qtrs
Comprehensive income (loss) attributable to Tanke Biosciences Corporation	`ComprehensiveIncomeNetOfTax`	$370.88K	USD	1 Quarter
Comprehensive income (loss) attributable to Tanke Biosciences Corporation	`ComprehensiveIncomeNetOfTax`	$496.24K	USD	1 Quarter
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.04	USD	2 Qtrs
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.03	USD	2 Qtrs
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$0.01	USD	1 Quarter
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$0.02	USD	1 Quarter
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	13.32M	shares	2 Qtrs
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	13.32M	shares	2 Qtrs
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	13.32M	shares	1 Quarter
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	13.32M	shares	1 Quarter

Cash Flow Statement 74 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$-563.16K	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$115.68K	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$272.41K	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-398.56K	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$244.56K	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$386.37K	USD	2 Qtrs
Amortization of discount on convertible notes payable	`AmortizationOfFinancingCosts`	$1.38M	USD	2 Qtrs
Amortization of discount on convertible notes payable	`AmortizationOfFinancingCosts`	-	USD	1 Quarter
Amortization of discount on convertible notes payable	`AmortizationOfFinancingCosts`	$690.90K	USD	1 Quarter
Amortization of discount on convertible notes payable	`AmortizationOfFinancingCosts`	$402.39K	USD	2 Qtrs
Amortization of capitalized offering costs	`OtherAmortizationOfDeferredCharges`	$115.69K	USD	2 Qtrs
Amortization of capitalized offering costs	`OtherAmortizationOfDeferredCharges`	$397.27K	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$353.48K	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-102.21K	USD	2 Qtrs
Inventories	`IncreaseDecreaseInInventories`	$69.14K	USD	2 Qtrs
Inventories	`IncreaseDecreaseInInventories`	$584.62K	USD	2 Qtrs
Note receivables and payables - related parties	`IncreaseDecreaseInDueFromRelatedParties`	-	USD	2 Qtrs
Note receivables and payables - related parties	`IncreaseDecreaseInDueFromRelatedParties`	$-239.48K	USD	2 Qtrs
Other receivables	`IncreaseDecreaseInOtherReceivables`	$365.15K	USD	2 Qtrs
Other receivables	`IncreaseDecreaseInOtherReceivables`	$103.68K	USD	2 Qtrs
Deferred tax asset	`IncreaseDecreaseInDeferredIncomeTaxes`	$490.00	USD	2 Qtrs
Deferred tax asset	`IncreaseDecreaseInDeferredIncomeTaxes`	$556.00	USD	2 Qtrs
Prepayments	`IncreaseDecreaseInPrepaidExpense`	$-308.28K	USD	2 Qtrs
Prepayments	`IncreaseDecreaseInPrepaidExpense`	$-190.56K	USD	2 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$25.63K	USD	2 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-8.88K	USD	2 Qtrs
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$40.25K	USD	2 Qtrs
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$-134.74K	USD	2 Qtrs
Advance from government grant	`IncreaseDecreaseInDeferredRevenue`	$-105.78K	USD	2 Qtrs
Advance from government grant	`IncreaseDecreaseInDeferredRevenue`	$44.14K	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$196.51K	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-202.72K	USD	2 Qtrs
Other payables and accrued liabilities	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$289.45K	USD	2 Qtrs
Other payables and accrued liabilities	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$-86.06K	USD	2 Qtrs
Income tax payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$259.80K	USD	2 Qtrs
Income tax payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$73.57K	USD	2 Qtrs
Advance from customer	`IncreaseDecreaseInCustomerAdvances`	$164.41K	USD	2 Qtrs
Advance from customer	`IncreaseDecreaseInCustomerAdvances`	-	USD	2 Qtrs
Net cash (used in) provided by operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-235.77K	USD	2 Qtrs
Net cash (used in) provided by operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$2.28M	USD	2 Qtrs
Increase in loans to customer and supplier	`IncreaseDecreaseInAccountsAndOtherReceivables`	$376.03K	USD	2 Qtrs
Increase in loans to customer and supplier	`IncreaseDecreaseInAccountsAndOtherReceivables`	-	USD	2 Qtrs
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$388.35K	USD	2 Qtrs
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.36M	USD	2 Qtrs
Purchase of intangible assets	`PaymentsToAcquireIntangibleAssets`	$482.22K	USD	2 Qtrs
Purchase of intangible assets	`PaymentsToAcquireIntangibleAssets`	$31.71K	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.39M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.25M	USD	2 Qtrs
Change in restricted cash	`IncreaseDecreaseInRestrictedCashAndInvestmentsForOperatingActivities`	$-231.84K	USD	2 Qtrs
Change in restricted cash	`IncreaseDecreaseInRestrictedCashAndInvestmentsForOperatingActivities`	$-123.59K	USD	2 Qtrs
Payment on convertible notes	`RepaymentsOfConvertibleDebt`	$160.84K	USD	2 Qtrs
Payment on convertible notes	`RepaymentsOfConvertibleDebt`	-	USD	2 Qtrs
Proceeds from long-term borrowings	`ProceedsFromIssuanceOfLongTermDebt`	$961.20K	USD	2 Qtrs
Proceeds from long-term borrowings	`ProceedsFromIssuanceOfLongTermDebt`	$967.63K	USD	2 Qtrs
Principal payments for long-term borrowings	`RepaymentsOfLongTermDebt`	-	USD	2 Qtrs
Principal payments for long-term borrowings	`RepaymentsOfLongTermDebt`	$961.20K	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$71.00K	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$1.09M	USD	2 Qtrs
Effect of exchange rate fluctuations on cash and cash equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$111.85K	USD	2 Qtrs
Effect of exchange rate fluctuations on cash and cash equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$210.96K	USD	2 Qtrs
Net (decrease) increase in cash	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$2.33M	USD	2 Qtrs
Net (decrease) increase in cash	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-1.44M	USD	2 Qtrs
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$4.72M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$10.03M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$6.17M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$7.70M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$4.72M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$10.03M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$6.17M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$7.70M	USD	Point-in-time
Cash paid for interest	`InterestPaid`	$37.80K	USD	2 Qtrs
Cash paid for interest	`InterestPaid`	$138.75K	USD	2 Qtrs
Cash paid for income taxes	`IncomeTaxesPaidNet`	$50.14K	USD	2 Qtrs
Cash paid for income taxes	`IncomeTaxesPaidNet`	$184.23K	USD	2 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.